Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL12 monomer
- Development stage
- Preclinical
- Lead developer
- Medical College of Wisconsin
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal
01
Overview
CXCL12 monomer, specifically the engineered 'locked' monomeric variant known as L121, is a structural variant of the chemokine CXCL12 (also known as Stromal Cell-Derived Factor 1 or SDF-1). While wild-type CXCL12 exists in a concentration-dependent equilibrium between monomers and dimers, L121 is designed to remain in a monomeric state. In the context of pancreatic ductal adenocarcinoma (PDAC), the monomeric form of CXCL12 acts as a pro-migratory agonist of the CXCR4 receptor. This is contrasted with the dimeric form (L122) or high concentrations of wild-type CXCL12, which favor dimerization and induce cytostasis and anti-migratory effects via calcium/calmodulin-kinase II and AMPK signaling pathways. Research into these structural variants aims to develop biased agonists as biologic therapies to selectively disrupt cancer metastasis.
- Other names
- monomeric CXCL12L121L-121L 121
02
Targets
CXCR7 (CXC chemokine receptor 7)CXCR4 (C-X-C motif chemokine receptor 4)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on CXCL12 monomer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL12 monomer.